Landry Benjamin sold $141K of HCAT
Landry Benjamin (General Counsel) sold 99,478 shares of Health Catalyst, Inc. (HCAT) at an average of $1.42 ($1.39–$1.43, $0.14M total) across 2 trades over 2026-11-11 to 2026-11-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest in size and likely to have limited effect on HCAT's share price, though it may add slight negative bias.
Market read
A routine insider sale with limited market impact; traders may monitor for any follow‑on activity but no immediate action is required.
What to watch
The 10b5‑1 plan suggests the sale was pre‑scheduled, reducing the informational content of the transaction.
Background
SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.
Ticker impact
General Counsel Landry Benjamin sold ~99,500 shares for $141K via a 10b5‑1 plan, reducing his stake to 251,894 shares.
likely slight downward pressure as investors price in the insider sell.
Insider sales, especially by a senior officer, often lead to modest negative sentiment; the transaction size is small relative to market cap.
Market effects
Minimal impact on the health‑tech sector; the sale is company‑specific.
None
None
Counterpoint
The sale could be routine under a pre‑arranged plan and not indicative of any fundamental issue.
Key entities
- CompanyHealth Catalyst, Inc.
Provider of data and analytics platforms for healthcare organizations.
- IndividualLandry Benjamin
General Counsel of Health Catalyst, executing a 10b5‑1 sale.



